Compositions and methods for treating psoriasis by Ganoderma lucidum (Reishi) polysaccharides

• US 7,947,283 B2
• Filed: 08/29/2008
• Issued: 05/24/2011
• Est. Priority Date: 08/30/2007
• Status: Expired due to Fees

• Current Assignee: Academia Sinica (Government of The Republic of China), Wyntek Corporation
• Original Assignee: Academia Sinica (Government of The Republic of China), Wyntek Corporation
• Inventors: Tu, Tseng-Rong, Su, Sung-Hsieh, Li, Chia-Feng, Wong, Chi-Huey, Fan, Eugene
• Primary Examiner(s): Flood; Michele
• Application Number:
  US12/231,112
• Publication Number:
  US 20090060940A1
• Time in Patent Office: 998 Days
• Field of Search: None
• US Class Current: 424/195.15
• CPC Class Codes: A61K 36/074 Ganoderma
• CPC Class Codes: A61P 17/06 Antipsoriatics

Abstract

A method for treating psoriasis by providing a pharmaceutical composition containing at least Ganoderma lucidum extract and administering a therapeutically effective amount of the composition to a patient in need thereof. Also disclosed is a method for treating psoriasis by first purifying Ganoderma lucidum extract into at least one fraction, then providing a pharmaceutical composition comprising at least one of the Ganoderma lucidum fractions, and administering a therapeutically effective amount of the composition to a patient in need thereof. A method for alleviating symptoms of psoriasis is disclosed. The symptoms of psoriasis are alleviated by providing a pharmaceutical composition containing at least Ganoderma lucidum extract and administering an amount of the composition effective to increase at least one of an IL-10 and IL-1Ra expression, whereby the symptoms of psoriasis are ameliorated.

Claims

1. A method for treating psoriasis, the method comprising

providing a pharmaceutical composition containing at least a sodium hydroxide (NaOH) extract of Ganoderma lucidum;

and

administering a therapeutically effective amount of the composition to a patient in need thereof to increase IL-10 expression in the patient.

2. The method of claim 1 wherein said composition is administered intravenously, intradermally, subcutaneously, orally, transdermally, transmucosally, or rectally.

3. The method of claim 1 wherein said composition is formulated as a cream, gel, salve, ointment, solution, tablet, capsule, spray, or patch.

4. A method for treating psoriasis comprising

providing a NaOH extract of Ganoderma lucidum;

purifying the Ganoderma lucidum extract into at least one fraction;

providing a pharmaceutical composition comprising at least one Ganoderma lucidum fraction; and

administering a therapeutically effective amount of the composition to a patient in need thereof wherein the fraction increases IL-10expression in the patient.

5. The method of claim 4 wherein said composition is administered intravenously, intradermally, subcutaneously, orally, transdermally, transmucosally, or rectally.

6. The method of claim 4 wherein said composition is formulated as a cream, gel, salve, ointment, solution, tablet, capsule, spray, or patch.

7. The method of claim 4 wherein said fraction comprises at least one fucose-containing glycoprotein.

8. A method for alleviating symptoms of psoriasis, the method comprising

providing a pharmaceutical composition containing at least a NaOH extract of Ganoderma lucidum;

and

administering an amount of the composition effective to increase IL-10expression to a subject with psoriasis, whereby the symptoms of psoriasis are ameliorated.

9. The method of claim 8, further comprising:

fractionating the NaOH extract prior to administration, wherein the fraction comprises at least one fucose-containing glycoprotein.

10. The method of claim 8 wherein said composition is administered intravenously, intradermally, subcutaneously, orally, transdermally, transmucosally, or rectally.

11. The method of claim 8 wherein said composition is formulated as a cream, gel, salve, ointment, solution, tablet, capsule, spray, or patch.